Results 81 to 90 of about 166 (149)

Review on lipegfilgrastim

International Journal of Nanomedicine, 2015
Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of ...
Gasparic M, Leyman S
doaj  

Evolution of Biosimilar Medicines on the Romanian Pharmaceutical Market

Acta Pharmaceutica Hungarica, 2021
Emese Sipos, Emőke Rédai, Ibolya Fülöp   +2 more
openaire   +1 more source

Biosimilar Rituximab in ANCA‐Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To evaluate the six‐month effectiveness and safety of rituximab biosimilars compared to the originator in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and outcomes following originator to biosimilar switching. Methods We recruited adults with GPA or MPA treated with the rituximab originator or a biosimilar for ...
Arielle Mendel, Lillian Barra, Hassan Behlouli, Sasha Bernatsky, Alison H. Clifford, Jan Willem Cohen Tervaert, Natasha Dehghan, Aurore Fifi‐Mah, Jean‐Paul Makhzoum, Rosalie‐Sélène Meunier, Nataliya Milman, Medha Soowamber, Elaine Yacyshyn, Nader Khalidi, Christian Pagnoux   +14 more
wiley   +1 more source

Fostering medication review competence of pharmacy students: An assessment by students and their preceptors after advanced‐level practical internship

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2549-2560, August 2026.
Aims The aim of this study was to introduce a new assessment method for pharmacy students' real‐life competence in reviewing medications after obligatory advanced‐level practical internship in Finland. Methods The new medication review (MR) competence assessment method consisted of (1) a self‐assessment by pharmacy students and (2) a performance ...
Katja Leiman, Aleksi Westerholm, Tero Vahlberg, Noora Lias, Tanja Lindholm, Marja Airaksinen   +5 more
wiley   +1 more source

Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development

Biologics: Targets & Therapy
Ranjit Ranbhor,1 Priyanka Kulkarni2 1Business Development, Portfolio and Patents, Odin Pharmaceuticals LLC, Somerset, NJ, USA; 2Feliciano School of Business, Montclair State University, Montclair, NJ, USACorrespondence: Ranjit Ranbhor, Business ...
Ranbhor R, Kulkarni P
doaj  

The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)

Thrombosis Journal, 2017
Recently, the European Medicines Agency (EMA) authorized the introduction and marketing of Thorinane® and Inhixa®, biosimilars of the Low Molecular Weight Heparin (LMWH) enoxaparin.
Davide Imberti, Marco Marietta, Hernan Polo Friz, Claudio Cimminiello   +3 more
doaj   +1 more source

Anti‐PEG Antibodies From mRNA COVID‐19 Vaccines Affect In Vitro Measurements of Pegylated Drug Levels

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The recent adoption of mRNA‐based technology for vaccine development has led to widespread exposure to new vaccine components, such as polyethylene glycol (PEG), against which antibodies may be made. This study assesses the presence of anti‐PEG antibodies in human serum following SARS‐CoV‐2 vaccination, and if these antibodies could interfere ...
Elizaveta A. Svyatova, Zhuoming Liu, Robyn E. Becker, Jungeun M. Sung, Adetunji P. Fayomi, Jeffry A. Florian, James L. Weaver, Rodney Rouse, Kristina E. Howard   +8 more
wiley   +1 more source

Bridging the Pregnancy Knowledge Gap: A Real‐World Analysis of Medication Use and Drug–Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Jacqueline Williams, Rucha Sane, Amita Joshi, Kit Wun Kathy Cheung, Bianca Vora   +4 more
wiley   +1 more source

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

ClinicoEconomics and Outcomes Research, 2018
Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 Stephanie Korrer3 1West Cancer Center, Memphis, TN, USA; 2Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA; 3Health Economics ...
Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S   +6 more
doaj  

A PHARMACEUTICAL GUIDE TO ADALIMUMAB BIOSIMILARS

FARMACIA, 2022
openaire   +1 more source